UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from _____ to _____ Commission File Number: 001-41690 U.S. GOLDMINING INC. (Exact name of registrant as specified in its charter) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Nevada 37-1792147 (State or other jurisdicti ...

Financial Performance - Quoin reported a net loss of approximately $3.8 million for Q1 2025, compared to a net loss of approximately $2.3 million for the same period in 2024, reflecting an increase in losses of about 65.2% year-over-year[11] - The net loss for the period was $3.81 million, compared to a net loss of $2.32 million in the previous year, indicating an increase in losses of approximately 64.1%[19] - Basic loss per ADS was $6.50, compared to $3.87 for the same period last year, reflecting a significant increase in loss per share[19] - Total revenue for the three months ended March 31, 2025, was $3.95 million, compared to $3.57 million for the same period in 2024, representing a growth of approximately 10.6%[19] - Operating expenses for the period were $3.95 million, with general and administrative expenses at $1.58 million and research and development expenses at $2.37 million[19] - Quoin's total assets decreased from approximately $15.7 million as of December 31, 2024, to approximately $12.96 million as of March 31, 2025[18] - Total liabilities increased from approximately $6.5 million at the end of 2024 to approximately $7.03 million by March 31, 2025[18] - The company reported a significant increase in accumulated deficit, rising to approximately $58.98 million as of March 31, 2025, compared to $55.17 million at the end of 2024[18] - The weighted average number of ADS outstanding was 586,331, compared to 609,094 in the previous year, showing a decrease in outstanding shares[19] Clinical Progress - The company achieved significant clinical progress with QRX003, showing almost complete skin healing and elimination of pruritus in patients, allowing for the discontinuation of multiple prior medications[2] - The interim results from the pediatric Investigator Study indicated improvement from "Severe" to "Mild" on the Investigator's Global Assessment after six weeks of treatment[4] - A newly FDA-cleared study will evaluate whole-body application of QRX003 in up to 12 patients, aiming to generate extensive clinical data for Netherton Syndrome[12] Intellectual Property and Initiatives - Quoin expanded its patent portfolio with new filings for novel formulations targeting several rare skin diseases, potentially extending intellectual property protection through 2045[9] - The company launched the NETHERTON NOW awareness initiative to support and engage with the Netherton community and advocacy groups[6] Cash and Financial Outlook - As of March 31, 2025, Quoin had approximately $11.6 million in cash, cash equivalents, and marketable securities, which is expected to support operations into Q1 2026[10]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40386 ONEMEDNET CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 86-2076743 (State or other jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Delaware 86-2076743 (State or other jurisdiction of incorporation or organization) 6385 Old Shady Oak Road, Suite 250 Eden Prairie, Minnesota 55344 (Address of principal executive offices) (Zip Code) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE A ...

Financial Performance - Revenue for the six months ended March 31, 2025, was $2,424,000, a 6.7% increase from $2,272,000 in the same period of 2024[17] - Gross profit for the three months ended March 31, 2025, was $713,000, compared to $680,000 for the same period in 2024, reflecting a growth of 4.9%[17] - The net loss attributable to the company for the six months ended March 31, 2025, was $8,088,000, compared to a loss of $3,868,000 in the same period of 2024, representing a 109% increase in losses[17] - For the six months ended March 31, 2025, the net loss was $8,126 thousand, compared to a net loss of $3,868 thousand for the same period in 2024, representing a 110% increase in losses[23] - Basic and diluted net loss per share of common stock was $0.08 for the six months ended March 31, 2025, compared to $0.06 for the same period in 2024[17] - The company reported a consolidated net loss of $8,126 thousand for the six months ended March 31, 2025, compared to a net loss of $3,868 thousand for the same period in 2024[75] Operating Expenses - Operating expenses surged to $10,684,000 for the six months ended March 31, 2025, compared to $4,498,000 in the prior year, indicating a significant increase of 137%[17] - General and administrative expenses increased by $6,801 thousand, or approximately 275.9%, to $9,265 thousand for the six months ended March 31, 2025, compared to $2,464 thousand for the same period in 2024[93] - Research and development expenses for the six months ended March 31, 2025, were $804,000, down 35.6% from $1,247,000 in the same period of 2024[17] Cash Flow and Assets - Cash and cash equivalents decreased to $11,126,000 as of March 31, 2025, down from $14,566,000 on September 30, 2024, a decline of 23%[15] - Cash provided by operating activities was negative $8,076 thousand for the six months ended March 31, 2025, compared to negative $2,540 thousand for the same period in 2024[23] - The company reported cash, cash equivalents, and restricted cash of $11,126 thousand at the end of the period, down from $14,566 thousand at the beginning of the period[23] - As of March 31, 2025, cash and cash equivalents totaled $11.1 million, a decrease of approximately $3.5 million from $14.6 million at the end of the prior fiscal year[104] Investments and Financing - The company raised $19,792 thousand from the issuance of ordinary shares during the financing activities for the six months ended March 31, 2025[23] - Net cash provided by financing activities totaled $19,766 thousand for the six months ended March 31, 2025, compared to $10,339 thousand for the same period in 2024[110] - The company generated gross proceeds of approximately $3,644,726 from the exercise of warrants for 2,699,797 shares of Class B common stock in February 2025[45] Assets and Equity - Total assets increased to $57,179,000 as of March 31, 2025, up from $42,651,000 on September 30, 2024, representing a growth of 34%[15] - Total stockholders' equity increased to $55,859,000 as of March 31, 2025, from $41,738,000 on September 30, 2024, marking a growth of 33.8%[15] - The allowance for credit losses decreased to $103 thousand as of March 31, 2025, from $197 thousand as of September 30, 2024, indicating improved credit risk management[37] Revenue Streams - For the six months ended March 31, 2025, product revenue increased by $744 thousand, or approximately 111.0%, to $1,414 thousand, compared to $670 thousand in 2024[88] - Service/Rental revenue decreased significantly, reflecting the ongoing strategic shift towards the RaaS model[83] - Leasing revenue showed a notable increase over the six-month period, demonstrating the growing adoption of the RaaS model[83] Strategic Initiatives - The company has implemented robotic solutions in over 80 cities across the United States, addressing labor shortages in various service sectors[26] - The company aims to be a long-term partner to clients by providing a range of robotic solutions to enhance operational efficiency[26] - The company signed a Master Services Agreement (MSA) in April 2025 with a car retailer group with over 150 locations, marking a significant milestone in the expansion of its Robotics-as-a-Service (RaaS) strategy[70] - A new joint venture named Boyu Artificial Intelligence (Beijing) Technology Co., Ltd. was established in December 2024, focusing on the Asian market for service robots[65] Compliance and Reporting - The registrant filed various certifications in accordance with the Sarbanes-Oxley Act of 2002, including those from the Principal Executive Officer and Principal Financial Officer[31.1][31.2][32.1][32.2] - The report includes Inline XBRL Instance Document and Taxonomy Extension Documents for enhanced data presentation and analysis[101.INS][101.SCH][101.CAL][101.DEF][101.LAB][101.PRE] - The report was signed by the Chief Executive Officer and Chief Financial Officer on May 14, 2025, indicating compliance with regulatory requirements[130][131]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, INC. (Exact name of registrant as specified in its charter) British Columbia, Canada N/A (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-40789 Calidi Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 86-2967193 (State or other jurisdiction of incorporation or organization) ...

Financial Performance - The net loss for the three months ended March 31, 2025, was $5.1 million, with an accumulated deficit of $126.7 million as of the same date[242]. - The company has not generated any revenue from product sales and expects to incur significant and increasing expenses for the foreseeable future[241][244]. - The company has incurred significant operating losses since inception, primarily funded through private sales of common stock and convertible promissory notes[241]. - The net loss for Q1 2025 was $5.1 million, a reduction of 30% compared to a net loss of $7.2 million in Q1 2024[267]. - Research and development expenses for Q1 2025 were $2.4 million, a decrease of 12% from $2.7 million in Q1 2024[269]. - General and administrative expenses for Q1 2025 were $2.6 million, down 34% from $4.0 million in Q1 2024[270]. - Total operating expenses decreased by 25% to $5.1 million in Q1 2025 from $6.8 million in Q1 2024[267]. - Net cash used in operating activities was $7.1 million for the three months ended March 31, 2025, compared to $3.8 million for the same period in 2024, representing an increase of 86%[291][292]. - The company reported a net loss of $5.1 million for the three months ended March 31, 2025, a decrease from a net loss of $7.2 million in the same period of 2024[291][292]. - The total cash and restricted cash increased by $970,000 in the three months ended March 31, 2025, compared to a decrease of $806,000 in the same period of 2024, indicating a turnaround in cash flow[290]. Funding and Financial Position - The company anticipates needing substantial additional funding to support operations and pursue growth strategies, with potential financing through public or private equity offerings and debt financings[246]. - The company raised gross proceeds of $4.3 million from a public offering of 5,000,000 shares at $0.85 per share on January 10, 2025[275]. - The company entered into a Securities Purchase Agreement on March 28, 2025, resulting in gross proceeds of approximately $3.9 million[283]. - The company increased the maximum aggregate offering amount under the At The Market Offering Agreement from $5.1 million to $11.2 million on February 4, 2025[280]. - The company anticipates an increase in general and administrative expenses as it expands to support growth in research and development activities[262]. - The company raised substantial doubt about its ability to continue as a going concern due to insufficient cash on hand to support operations for at least one year[247]. - The company has concluded that it does not have sufficient cash on hand to support current operations for at least one year from the date of the financial statements issued, raising substantial doubt about its ability to continue as a going concern[297]. - The company anticipates that existing cash will not be sufficient to complete the development of product candidates CLD-101, CLD-201, and CLD-400, requiring further funding[298]. - The company plans to finance cash needs through public or private equity offerings, debt financings, or potential collaboration agreements, which may dilute ownership interests[299]. Research and Development - The FDA approved the IND application for CLD-201 (SuperNova™) in April 2025, with plans to commence a Phase 1 clinical trial by the end of 2025[237]. - A Phase 1b/2 clinical trial for CLD-101 (NeuroNova™) targeting newly diagnosed high-grade gliomas is dependent on the resumption of funding from National Cancer Institute grants, which were frozen in March 2025[235]. - The preclinical program CLD-400 (RTNova) is focused on targeting lung cancer and metastatic solid tumors, showing early signs of resistance to human humoral immunity[240]. - The company has engaged in early discovery research involving Adult Allogeneic Adipose-derived (AAA) stem cells for various therapeutic applications[238]. Management and Governance - Eric Poma, Ph.D., was appointed as CEO effective April 22, 2025, following the resignation of Allan Camaisa[251]. Market and Economic Conditions - The company is not currently exposed to significant market risk related to changes in interest rates or foreign currency exchange rates, but future operations may be subject to such fluctuations[306][307]. - Inflation has not had a material effect on the company's business, financial condition, or results of operations during the three months ended March 31, 2025, and 2024[308]. - The company is currently not exposed to significant market risk related to foreign currency exchange rates, but may face fluctuations in the future due to operations in Europe and Australia[307]. Regulatory and Reporting Status - The company qualifies as an "emerging growth company" (EGC) under the JOBS Act, allowing it to delay the adoption of certain accounting standards until they apply to private companies[309]. - The company is classified as a "smaller reporting company," with a market value of stock held by non-affiliates less than $700 million and annual revenue below $100 million in the most recently completed fiscal year[311]. - The company may continue to rely on exemptions from certain disclosure requirements as a smaller reporting company, including presenting only two years of audited financial statements[312]. - The company will avail itself of exemptions from providing an auditor's attestation report on internal control over financial reporting and reduced disclosure about executive compensation[313]. - Recent accounting standards are not expected to have a material impact on the company's financial statements or operations[314].

Revenue Performance - U.S. fee revenues for Q1 2025 decreased 85% to $2.7 million compared to $18.3 million in Q1 2024, primarily due to decreased crew utilization [81]. - Canadian fee revenues for Q1 2025 increased 48% to $12.5 million compared to $8.5 million in Q1 2024, driven by increased crew utilization and the use of single node channels [82]. - Total revenues for Q1 2025 were $16.1 million, down from $31.6 million in Q1 2024, including a $4.0 million decrease in reimbursable revenues [82]. - The company expects revenue to increase in the U.S. in Q2 2025 due to a strong backlog [76]. Operating Costs and Financial Performance - Total operating costs for Q1 2025 were $15.0 million, representing a 63% decrease from the same period in 2024 [88]. - Adjusted EBITDA for Q1 2025 was $2.3 million, compared to $7.6 million in Q1 2024 [94]. - Net cash provided by operating activities was $1.8 million for Q1 2025, compared to $1.9 million for the same period in 2024 [96]. Capital Expenditures and Investments - Capital expenditures for 2025 are budgeted at $6.0 million, with funding primarily from cash flow from operations and cash reserves [99]. - The company plans to invest in new single node channels to improve revenue and margins through enhanced crew efficiency [78]. Dividends and Shareholder Returns - A special cash dividend of $0.32 per share was declared on March 28, 2024, totaling approximately $9.9 million [100]. Debt and Financial Obligations - As of March 31, 2025, the company has outstanding short-term notes payable totaling $1.5 million, an increase from $168,000 as of December 31, 2024 [103]. - The company has finance leases of $2.2 million as of March 31, 2025, down from $2.4 million as of December 31, 2024 [104]. - The interest rates on outstanding notes payable to finance companies range from 6.35% to 9.74% [105]. - The aggregate maturities of finance leases for the period April 2025 to March 2026 amount to $836,000 [105]. - The Loan Agreement with Dominion Bank provided a secured revolving credit facility of up to $5 million, which was terminated on May 2, 2024 [101]. - As of March 31, 2025, the company has no outstanding letters of credit [102]. Risk Management - The company believes its capital resources will be adequate to meet current operational needs and finance 2025 capital expenditures through cash flow from operations [106]. - There has been no material change in the company's market risk profile during the three months ended March 31, 2025 [110]. - The company is exposed to foreign currency exchange rate risk due to operations in Canada [111]. - The company has not entered into any hedge arrangements or derivative financial instruments [111].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41293 ASPIRE BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 33-3467744 (State or other juris ...